1. Pozniack A, Gallant JE, De Jesus E, et al. Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients Virologic, Immunologic, and Morphologic Changes—A 96-Week Analysis JAIDS 2006; 43:535-540.
  2. Gallant JE, Staszewski S, Pozniack A, et al. Efficacy and safety of Tenofovir DF vs Stavudine in combination therapy in antiretroviral naive patients. A 3-year randomized trial JAMA 2004; 292:191-201.
  3. Sax PE, Tierney C, Collier AC, et al; AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009; 361(23):2230-2240.
  4. Raffi F, Babiker AG, Richert L, for the NEAT001/ANRS143 Study Group. Ritonavir-boosted darunavir combined with raltegravir or tenofoviremtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet 2014; 384:1942-51.
  5. Lee F, Anim J, Carr A. Efficacy of Initial Antiretroviral Therapy for HIV-1 Infection in Adults: A Systematic Review and Meta-Analysis of 114 Studies with up to 144 Weeks’ Follow-Up. PLoS ONE 20149(5): e97482. doi:10.1371/journal.pone.00974.
© Effetti srl